The Alzheimer disease BIN1 locus as a modifier of GBA-associated Parkinson disease

被引:20
|
作者
Gan-Or, Z. [1 ,3 ]
Amshalom, I. [1 ,3 ]
Bar-Shira, A. [1 ]
Gana-Weisz, M. [1 ]
Mirelman, A. [2 ]
Marder, K. [4 ]
Bressman, S. [5 ]
Giladi, N. [3 ]
Orr-Urtreger, A. [1 ,3 ]
机构
[1] Tel Aviv Sourasky Med Ctr, Genet Inst, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Sourasky Med Ctr, Dept Neurol, Movement Disorders Unit, Parkinson Ctr, IL-64239 Tel Aviv, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[4] Columbia Univ, Dept Neurol, Columbia Presbyterian Med Ctr, New York, NY 10032 USA
[5] Beth Israel Deaconess Med Ctr, Dept Neurol, New York, NY 10003 USA
基金
以色列科学基金会;
关键词
BIN1; GBA; Genetics; Parkinson disease; GENOME-WIDE ASSOCIATION; MUTATIONS; RISK; METAANALYSIS;
D O I
10.1007/s00415-015-7868-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
GBA mutations are among the most common genetic risk factors for Parkinson disease (PD) worldwide. We aimed to identify genetic modifiers of the age at onset (AAO) in GBA-associated PD. The study included a genome-wide discovery phase, including a cohort of 79 patients with the GBA p.N370S mutation, and candidate validation and replication analyses of 8 SNPs in patients with mild (n = 113) and severe (n = 41) GBA mutations. Genotyping was performed using the Affymetrix human SNP 6.0 array and TaqMan assays. In the genome-wide phase, none of the SNPs passed the genome-wide significance threshold. Eight SNPs were selected for further analysis from the top hits. In all GBA-associated PD patients (n = 153), the BIN1 rs13403026 minor allele was associated with an older AAO (12.4 +/- A 5.9 years later, p = 0.0001), compared to patients homozygous for the major allele. Furthermore, the AAO was 10.7 +/- A 6.8 years later in patients with mild GBA mutations, (p = 0.005, validation group), and 17.1 +/- A 2.5 years later in patients with severe GBA mutations (p = 0.01, replication). Our results suggest that alterations in the BIN1 locus, previously associated with Alzheimer disease, may modify the AAO of GBA-associated PD. More studies in other populations are required to examine the role of BIN1-related variants in GBA-associated PD.
引用
收藏
页码:2443 / 2447
页数:5
相关论文
共 50 条
  • [31] Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease
    Tan, Meng-Shan
    Yu, Jin-Tai
    Tan, Lan
    TRENDS IN MOLECULAR MEDICINE, 2013, 19 (10) : 594 - 603
  • [32] iPSC-derived in vitro striatal circuits to understand GBA-associated Parkinson's disease
    Do, Quyen
    Ng, Bryan
    Bengoa-Vergniory, Nora
    Wade-Martins, Richard
    JOURNAL OF NEUROCHEMISTRY, 2022, 162 : 96 - 97
  • [33] Oligomeric alpha-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson's disease
    Emelyanov, A. K.
    Baydakova, G. V.
    Andoskin, P. A.
    Nikolaev, M. A.
    Senkevich, K. A.
    Milyukhina, I. V.
    Yakimovskii, A. F.
    Timofeeva, A. A.
    Fedotova, E. Y.
    Nuzhnyi, E. P.
    Illarioshkin, S. N.
    Zakharova, E. Y.
    Pchelina, S. N.
    MOVEMENT DISORDERS, 2016, 31 : S214 - S215
  • [34] Ambroxol treatment of primary macrophages derived from patients with GBA-associated Parkinson's disease
    Kopytova, A.
    Nikolaev, M.
    Senkevich, K.
    Baydakova, G.
    Miliukhina, I.
    Zakharova, E.
    Pchelina, S.
    MOVEMENT DISORDERS, 2019, 34
  • [35] The Mechanistic Role of Bridging Integrator 1 (BIN1) in Alzheimer’s Disease
    Peirong Gao
    Lingqi Ye
    Hongrong Cheng
    Honglei Li
    Cellular and Molecular Neurobiology, 2021, 41 : 1431 - 1440
  • [36] Contribution of the SNCA gene and genes involved in autophagy in the pathogenesis of GBA-associated parkinson's disease
    Basharova, K.
    Bezrukova, A.
    Bogdanova, D.
    Senkevich, K.
    Gracheva, E.
    Miliukhina, I.
    Emelyanov, A.
    Pchelina, S.
    Usenko, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 44 : S11 - S11
  • [37] Cardiovascular autonomic function in GBA-associated Parkinson's disease: a cross-sectional study
    De Santis, T.
    Cocco, A.
    Polverino, P.
    Polvere, V.
    Valente, E. M.
    Albanese, A.
    MOVEMENT DISORDERS, 2023, 38 : S472 - S472
  • [38] Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson’s disease enrolled in PPMI
    Huh Y.E.
    Park H.
    Chiang M.S.R.
    Tuncali I.
    Liu G.
    Locascio J.J.
    Shirvan J.
    Hutten S.J.
    Rotunno M.S.
    Viel C.
    Shihabuddin L.S.
    Wang B.
    Sardi S.P.
    Scherzer C.R.
    npj Parkinson's Disease, 7 (1)
  • [39] Is the GBA2 a new modifier for Gauchers's disease and GBA1-related Parkinson's disease?
    Nakanishi, E.
    Uemura, N.
    Akiyama, H.
    Kinoshita, M.
    Yamakado, H.
    Takeda, S.
    Hirabayashi, Y.
    Takahashi, R.
    MOVEMENT DISORDERS, 2017, 32
  • [40] Pharmacokinetics and biomarker responses in patients with Gaucher disease type 3 or GBA-associated Parkinson's disease treated with venglustat
    Peterschmitt, M. Judith
    Sharma, Jyoti
    Karetsky, Lina
    Ji, Allena
    Pandya, Shirali
    Freisens, Selena
    Minini, Pascal
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S96 - S96